Biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) on Friday announced European Commission approval of sugemalimab (Cejemly) in combination with platinum-based chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC).
The drug becomes the first Chinese-developed anti-PD-L1 monoclonal antibody approved in Europe.
This approval was based on the GEMSTONE-302 Phase 3 trial, which demonstrated improved survival rates.
CStone has partnered with Swiss pharmaceutical company Ewopharma for commercialisation in Central and Eastern Europe and in Switzerland. The company is seeking further partnerships for Western Europe and other regions.
CStone plans to submit additional applications to the European Medicines Agency for indications in other cancer types.
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Life Molecular Imaging's [18F]PI-2620 Injection receives US FDA Fast Track Designation
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Find Therapeutics FTX-101 IND application receives US FDA approval for Chronic Optic Neuropathy
Cantargia updates clinical trial timelines for nadunolimab
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
EURneffy approved in EU for needle-free anaphylaxis treatment